Las Vegas – More than 350 industry professionals in cannabis and psychedelics gathered for reMind’s debut Psychedelics Business Forum on Tuesday, November 15th for a pre-conference event at MJBizCon at the Westgate Las Vegas Resort & Casino.
The one-day conference and networking event addressed the most important topics in the psychedelics industry today, including the latest drug research, policy changes, investment opportunities, market trends, and cultural issues.
With an audience of mostly first-time psychedelics business conference attendees, the day started with a keynote address from Ethan Nadelmann, founder of Drug Policy Alliance, who described the opportunities and responsibilities that business owners face in the emerging psychedelics industry.
The morning sessions progressed from a medical review of current drug trials, a breakdown of the legal landscape, and an analysis of the rapidly evolving consumer marketplace and psychedelics usage trends.
Panels of highly respected industry thought leaders explored the similarities and differences between the cannabis and psychedelics industries, how investors should approach current opportunities given today’s economic realities, and what entrepreneurs need to know to prepare for future developments in the psychedelics space.
In a particularly poignant session, U.S. combat veteran Neil Markey shared his personal struggle with PTSD, the profound healing he found in psilocybin and meditation, and how he brought these experiences to his role as founder of Beckley Retreats. The day ended with a networking reception where attendees got the opportunity to connect with speakers and explore the forum’s topics in greater depth.
reMind is a new media and events platform committed to connecting and educating diverse communities to responsibly grow the business of psychedelics. Once stigmatized substances, these breakthrough medicines are now proving to be powerful tools in the fight against the global mental health crisis.
“Today, a record 53 million people in the U.S. alone are suffering from a mental illness, such as depression, addiction or PTSD, according to the CDC. With psychedelics-related legislation, investment, and health advancements announced nearly every day, there’s never been a better time to launch a resource like reMind. It was a privilege to connect the brightest minds and most passionate professionals across the business of psychedelics.” — Sara Vaughn, VP, brand leader of reMind